Table 4.
Notch-associated lncRNAs impact on CRC clinical outcome
| Notch-associated lncRNA |
CRC clinical outcome | Refs. | |||
|---|---|---|---|---|---|
| Size, TNM; Tumor stage | Disease-free survival/ OS | Recurrence/ Metastasis |
Hazard ratio (HR) | ||
| FOXD2-AS1 | – | Poor OS | – | 2.245 | [190] |
| FAM83H‑AS1 |
Larger size ≥ 5 cm, advanced stage III-IV |
Poor OS | – | 1.542; 95% confidence interval (CI) (1.115–2.135) | [126, 192] |
| LINC00152 | advanced stage III-IV | Poor disease-free survival & OS | Recurrence in Oxaliplatin-receiving patients | 3.825; 95%(CI) (1.723–8.493) | [127, 194] |
| LINC00707 |
Larger size ≥ 5 cm, advanced stage III-IV |
Poor OS | Lymphatic metastasis & distant metastasis |
4.255; 95%(CI) (1.560–11.610) |
[130, 196] |
| DSCAM-AS1 | Advanced stage III-IV | Poor OS | Metastasis | – | [128] |
| ENST00000455974 | – | Poor progression free survival |
14.404; 95% (CI) (1.785, 116.242) |
[131] | |
| UICLM |
Larger size, advanced stage III-IV |
Worse progression free survival | Liver metastasis |
2.13; 95%(CI) (1.77–3.06) |
[135] |
| LUNAR1 | Advanced stage III-IV | Unfavorable disease-free survival & OS | TNM | 3.25; 95%(CI) (1.98–5.31) | [188] |